



0420

3737  
#4

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231 on May 7, 2002.

INFORMATION DISCLOSURE STATEMENT  
Examining Group 3737  
Patent Application  
Docket No. UF-265CXC1  
Serial No. 10/075,490 #4

*Frank C Eisenschenk*

Frank C. Eisenschenk, Ph.D., Patent Attorney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (Unassigned)  
Art Unit : 3737  
Applicant(s) : Julie A. Johnson  
Serial No. : 10/075,490  
Filed : February 12, 2002  
Conf. No. : 8778  
For : BETA-ADRENOCEPTOR GENETIC POLYMORPHISMS AND OBESITY

RECEIVED  
MAY 14 2002  
TC 3700 MAIL ROOM

Assistant Commissioner for Patents  
Washington, D.C. 20231


INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. §§ 1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. § 1.56, the references listed on the attached form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

Applicants respectfully assert that the substantive provisions of 37 C.F.R. §§ 1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,



Frank C. Eisenschenk, Ph.D.

Patent Attorney

Registration No. 45,332

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: 2421 N.W. 41<sup>st</sup> Street, Suite A-1  
Gainesville, FL 32606-6669

FCE/an

Attachments: Form PTO SB/08A&B (2 pages)  
References listed thereon